Calyculin A-induced endothelial cell shape changes are independent of [Ca2+]i elevation and may involve actin polymerization  by Leung, Yuk Man et al.
Calyculin A-induced endothelial cell shape changes are independent of
[Ca2þ]i elevation and may involve actin polymerization
Yuk Man Leung , Tony K. Kwan, Chiu Yin Kwan, Edwin E. Daniel
Department of Medicine, Faculty of Health Sciences, McMaster University, 1200 Main Street West, Hamilton, ON, Canada L8N 3Z5
Received 9 January 2001; received in revised form 13 December 2001; accepted 13 December 2001
Abstract
Changes in endothelial cell (EC) shape result in inter-EC gap formation and subsequently regulate transendothelial
passage. In this work, we investigated the effects of protein phosphorylation (induced by inhibition of protein
phosphatases) on EC shape changes. Treatment of bovine pulmonary artery endothelial cells (BPAEC) with calyculin A
(100 nM, an inhibitor of protein Ser/Thr phosphatases 1 and 2A) resulted in cell retraction, surface bleb formation and cell
rounding. Trypan blue and electrophysiological experiments suggested that the plasma membrane of these rounded cells
maintained functional integrity. Calyculin A-induced morphological changes were strongly inhibited by staurosporine, but
not affected by specific inhibitors of the myosin light chain (MLC) kinase, protein kinases A, C and G, and tyrosine
kinases. The calyculin A effects were not mimicked by phorbol myristate acetate, dibutyryl cAMP, 8-bromo-cGMP or
ionomycin. Cytochalasin B (an inhibitor of actin polymerization) almost completely abolished such shape changes while
colchicine (an inhibitor of microtubule polymerization) had no inhibitory effect at all. Ca2þ imaging experiments showed
that the morphological changes were not associated with any global or local cytosolic Ca2þ concentration ([Ca2þ]i)
elevation. The results suggest that calyculin A unmasked the basal activities of some protein Ser/Thr kinases other than
MLC kinase and protein kinases A, C and G; these unknown kinases might cause BPAEC shape changes by a mechanism
involving actin polymerization but not [Ca2þ]i elevation. 9 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
One of the important functions of endothelial cell
(EC) is the regulation of transendothelial passage (i.e.
exchange between blood and tissue) via changes in
EC shape and the resultant inter-EC gap formation
[1^6]. For instance, in£ammatory agents such as his-
tamine and thrombin have been known to cause EC
retraction and contraction. Thus, while still maintain-
ing their typical cobblestone morphology, EC slightly
round o¡ and result in formation of small inter-EC
gaps. These EC shape changes have been proposed to
involve actin^myosin interaction and/or alteration in
cell^cell and cell^matrix contacts. Actin^myosin inter-
action (contraction) is known to be promoted by EC
cytosolic Ca2þ concentration ([Ca2þ]i) elevation and
subsequent myosin light chain (MLC) kinase activa-
tion and MLC phosphorylation [1^6]. Regulation of
cell^cell and cell^matrix contacts is less understood.
However, protein kinase C (PKC) has been shown to
phosphorylate vinculin and talin, two proteins which
interact with plasma membrane and actin ¢laments
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[4,5]. Such phosphorylation is believed to be respon-
sible for decreased cell^cell/cell^matrix contact and
subsequently EC retraction.
Calyculin A is a potent and selective inhibitor of
protein Ser/Thr phosphatases 1 and 2A (PP1 and 2A)
[7] and thus increases the apparent activities of pro-
tein kinases [8]. Interestingly, calyculin A has been
demonstrated to uncover the basal activities of some
unknown protein kinases [9^11]. It has been shown
to cause contraction of bovine pulmonary artery EC
(BPAEC) and rat pulmonary microvascular EC
[12,13]. One mechanism could be enhancement of
MLC kinase activity. However, in rat pulmonary
microvascular EC, calyculin A e¡ects are indepen-
dent from MLC phosphorylation [13]. In this work,
calyculin A was shown to cause much drastic shape
changes in BPAEC: cell retraction and rounding,
surface bleb formation, followed by bleb withdrawal
and complete cell rounding, a phenomenon rarely
reported. We provide evidence that these shape
changes may be due to the basal activities of some
unknown staurosporine-sensitive protein Ser/Thr ki-
nases other than MLC kinase, protein kinases C, A
and G. It has been shown in rat pulmonary micro-
vascular EC that calyculin A could, but [Ca2þ]i ele-
vation could not, trigger cell contraction [14]. Here
we show by Ca2þ imaging technique that the drastic
shape changes in calyculin A-treated BPAEC did not
involve any global or local [Ca2þ]i change, providing
direct evidence that there are EC shape change mech-
anism(s) independent from [Ca2þ]i elevation. Calycu-
lin A has been shown to cause reorganization of
several cytoskeletal components in various cell types
[15^20]. We found that actin polymerization appears
to account for the calyculin A-induced shape
changes. Thus, this appears to be an EC shape
change mechanism in addition to the ones already
recognized, which depend on [Ca2þ]i elevation/ac-
tin^myosin interaction and enhanced PKC activity.
The physiological signi¢cance of this EC shape
change mechanism is discussed.
2. Materials and methods
2.1. Endothelial cell culture
BPAEC (cell line No. CCL 209 from ATCC,
Rockville, MD, USA) were grown in MEM (mini-
mum essential medium, Gibco, Grand Island, NY,
USA) supplemented with 20% foetal bovine serum
(Gibco), gentamicin (0.1%, Gibco) and fungizone
(0.1%, Gibco) in a humid atmosphere of 95% air/
5% CO2 at 37‡C. Trypsin (0.5%) was used to dis-
lodge cells in each passage. Another BPAEC cell
line (CRL-1733, also from ATCC) was also con-
¢rmed later by us to be similarly sensitive to calycu-
lin A as the CCL 209 line.
2.2. Solutions and drugs
Hanks’ bu¡ered saline solution (HBSS), composed
of (mM) 138 NaCl, 5.3 KCl, 0.8 MgSO4, 1.2 CaCl2,
0.44 KH2PO4, 0.34 Na2HPO4, 5 glucose and 10
HEPES and pH adjusted to 7.4 with NaOH, was
used as the physiological extracellular solution for
all experiments. The pipet (intracellular) solution
had the following composition (mM): 140 KCl,
1 MgCl2, 0.5 CaCl2, 4 Na2ATP, 0.3 EGTA and 10
HEPES, pH adjusted to 7.2 with KOH. All the so-
lutions in patch clamp experiments were ¢ltered
(pore size 0.45 Wm) before use. Phorbol myristate
acetate (PMA), ATP, dibutyryl cAMP, 8-bromo-
cGMP, 4-chloro-3-ethyl phenol (CEP), genistein, col-
chicine, cytochalasin B and ionomycin were obtained
from Sigma (St. Louis, MO, USA). Calyculin A and
okadaic acid were from Research Biochemicals Inter-
national (Natick, MA, USA). Staurosporine, ML-7,
H-8 and GF-109203 X were purchased from Calbio-
chem (Richmond, CA, USA). Fura-2 acetoxymethyl
ester (AM) was obtained from Molecular Probes
(Eugene, OR, USA).
2.3. Examination of cell morphology
BPAEC, grown in 12-well culture plates to about
60^80% con£uence, were washed and bathed in
HBSS. They were then treated with various drugs
and incubated at room temperature. All protein ki-
nase inhibitors were added 5 min before calyculin A.
Colchicine and cytochalasin B were added 30 min
before calyculin A. At the desired time point, 50 cells
were counted at random in each well under a light
microscope. Quiescent cells were £at and polygonal,
and were counted as ‘cobblestone shape cells’. After
calyculin A treatment, cells initially retracted, started
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rounding up and formed surface blebs. These cells
were counted as ‘blebby round cells’. After about
1 h, cell rounding became increasingly prominent,
with simultaneous withdrawal of blebs, so that by
2 h or so the majority of cells became almost com-
pletely spherical. These cells were counted as ‘bleb-
less round cells’.
2.4. Ca 2+ imaging
Experimental details for Ca2þ imaging experiments
have been described in our previous report [21].
BPAEC were plated on a recording chamber with a
glass coverslip bottom and left to settle overnight
before use. Cells were about 40^60% con£uent at
the time of experiment. For the £uorescent dye load-
ing, cells were washed and bathed in HBSS contain-
ing 2 WM fura-2 AM, and then incubated at 37‡C for
1 h. Thereafter, the cells were washed and bathed
again in HBSS. [Ca2þ]i of single BPAEC was studied
using a Ca2þ imaging system (Image-1/FL, Universal
Imaging Corp., West Chester, PA, USA) with a Zeiss
lamp (HBO 100W/DC, Carl Zeiss Canada, Don
Mills, ON, Canada) coupled to a Zeiss inverted
microscope (Zeiss IM 35) with a 100U oil immersion
lens and a numerical aperture of 1.25. Selected cells
were excited alternately at 340 and 380 nm, and the
emitted £uorescence was detected at 540 nm. Images
were integrated and collected by a Pulnix camera
(TM-720, Pulnix America, CA, USA). Time between
each ratio image was 3 s. The earliest fura-2 mea-
surement after calyculin A addition was thus within
3 s. Images were analyzed by assessing the £uores-
cence intensity of the cells for the course of the ex-
periment by use of the computer software Image-1/
FL. The latter program also enables a black back-
ground to be obtained via defocusing and refocusing
the cell images. All experiments were performed at
room temperature (22^24‡C).
2.5. Electrophysiology
Patch clamp experiments were performed as de-
scribed previously [22,23]. BPAEC were plated on a
small plastic culture dish and left to settle overnight
before use. They were about 40^60% con£uent at the
time of experiment. Cells were washed and then
bathed in HBSS. Electrodes were prepared from bo-
rosilicate glass capillary tubing using a patch elec-
trode puller (Model P80/PC; Sutter Instrument, No-
vato, CA, USA) and then heat polished. Electrode
resistance was 1.5^2.5 M6 when the electrodes were
¢lled with the pipet solution. Only isolated cells were
selected for recording to avoid problems arising from
possible electrical coupling with neighboring cells.
Standard patch clamp techniques for whole-cell re-
cordings were employed [24]. Currents were triggered
by applying voltage steps with pulse protocols driven
by an IBM-486 computer equipped with A-D and D-
A converters (AXOLAB 1100, Axon Instruments,
Foster City, CA, USA) and pCLAMP 5.5 programs
(Axon Instruments) and measured using an Axo-
patch-1C ampli¢er. Membrane potentials were re-
corded using the current clamp mode. Total plasma
membrane area was estimated by measuring the cell
capacitance, which was read from the dial setting of
the whole-cell capacitance compensation of the am-
pli¢er. Cell input resistance was calculated using pla-
teau current amplitudes elicited by 10 mV depolariz-
ing pulses (370 mV holding potential). Data were
¢ltered with a low pass Bessel ¢lter (33 dB at
1 kHz) and digitized on-line at a sampling frequency
of 5 kHz for subsequent computer analysis. Data
acquisition and analysis were performed using
pCLAMP 5.5 program and Axograph software
(Axon Instruments). All experiments were performed
at room temperature (22^24‡C).
To study the properties of blebby round cells,
BPAEC were treated with 100 nM calyculin A for
20 min^1 h and then subjected to cell^electrode con-
tact and electrophysiological measurements. BPAEC
were also treated with DMSO (solvent) for the con-
trol group.
2.6. Data analysis
Data are expressed as meanVS.E.M. Student’s un-
paired t-test was employed and di¡erences were con-
sidered signi¢cant when P6 0.05.
3. Results
3.1. Calyculin A-induced morphological changes
Fig. 1A shows a monolayer of quiescent BPAEC,
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which were planar and polygonal in shape (‘cobble-
stone’ morphology). After treatment of BPAEC with
calyculin A (100 nM) for around 10 min, cells re-
tracted and became rounded up, with the formation
of blebs at the cell surface (Fig. 1B). Cell rounding
became more prominent with withdrawal of blebs, so
that by 2 h of calyculin A treatment, the majority of
cells were almost completely spherical and without
surface blebs (Fig. 1C). These completely spherical
cells became loosely attached to the substratum,
but remained viable, as judged from their ability to
exclude trypan blue (viability s 97%; four experi-
ments). The e¡ects of okadaic acid (1 WM), a struc-
turally unrelated inhibitor of PP1 and 2A [7], on cell
morphology were also tested. However, this com-
pound did not cause any detectable morphological
changes (not shown; three experiments).
Fig. 2 shows a quanti¢cation of the calyculin A-
induced cell shape changes and their modulation by
protein kinase inhibitors. The percentage of cobble-
stone shape cells dropped rapidly after 100 nM caly-
culin A treatment (Fig. 2A), due to the formation of
blebby round cells (see below). Such a drop was sig-
ni¢cantly retarded by staurosporine (300 nM), a po-
tent but non-speci¢c protein kinase inhibitor, but
una¡ected by 30 WM GF-109203 X (speci¢c PKC
inhibitor) or 30 WM H-8 (selective cAMP- and
cGMP-dependent protein kinase inhibitor) (Fig.
2A). The percentage of blebby round cells rapidly
increased in 15 min of calyculin A treatment, but
then gradually dropped, because of the slow transi-
tion into blebless round cells (Fig. 2B). The rate of
blebby round cell formation was strongly retarded
by staurosporine (P6 0.05), but was not a¡ected
by GF-109203 X or H-8. The gradual increase in
percentage of blebless round cells after calyculin A
treatment was also strongly inhibited by staurospo-
rine (P6 0.05) but not a¡ected by H-8 (Fig. 2C).
Fig. 1. Morphology of untreated and calyculin A-treated
BPAEC. (A) Untreated BPAEC exhibited typical cobblestone
morphology. (B,C) BPAEC treated with 100 nM calyculin A
for about 30 min and 2 h, respectively: initial cell rounding
with bleb formation was followed by a gradual bleb withdrawal
and increase in rounding. Magni¢cation= 204U.
Fig. 2. Quanti¢cation of cell shape changes induced by 100 nM
calyculin A in the absence and presence of protein kinase inhib-
itors. A^C show the % changes of cells of di¡erent morpholo-
gies (see Section 2) with time after exposure to various drugs.
F, DMSO as solvent control; b, 100 nM calyculin A; E, 100
nM calyculin A plus 300 nM staurosporine; a, 100 nM calycu-
lin A plus 30 WM GF-109203 X; R, 100 nM calyculin A plus
30 WM H-8. All protein kinase inhibitors were added 5 min be-
fore calyculin A. Results are meanVS.E.M. of four experi-
ments.
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GF-109203 X partially inhibited such a process
(P6 0.05). When a lower concentration of calyculin
A (10 nM) was used, the rates of formation of blebby
round cells and blebless round cells were both slower
than when 100 nM calyculin A was used (Fig. 3B,C).
The rate of formation of blebby round cells was
strongly retarded by staurosporine (P6 0.05) and
una¡ected by GF-109203 X or H-8 (Fig. 3B). The
rate of blebless round cell formation was strongly
attenuated by staurosporine (P6 0.05), less strongly
attenuated by GF-109203 X (P6 0.05) and not af-
fected by H-8 (Fig. 3C).
Fig. 3. Quanti¢cation of cell shape changes induced by 10 nM
calyculin A in the absence and presence of protein kinase inhib-
itors. Experimental protocols, drug concentrations and symbols
in graphs are identical to those described in Fig. 2, except that
calyculin A was used at 10 nM. Results are meanVS.E.M. of
four experiments.
Fig. 4. Quanti¢cation of cell shape changes induced by 100 nM
calyculin A in the absence and presence of colchicine and cyto-
chalasin B. A^C show the % changes of cells of di¡erent mor-
phologies (see Section 2) with time after exposure to various
drugs. F, DMSO as solvent control; b, 100 nM calyculin A; E,
100 nM calyculin A plus 30 WM colchicine; a, 100 nM calycu-
lin A plus 30 WM cytochalasin B. Colchicine and cytochalasin
B were added 30 min before calyculin A. Results are meanV
S.E.M. of three experiments.
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Calyculin A enhances the apparent activities of
protein kinases by inhibiting protein phosphatases.
We next tested if the e¡ects of calyculin A on cell
morphology could be mimicked by some protein ki-
nase activators. PMA (300 nM), an activator of
PKC, 8-bromo-cGMP (1 mM), an activator of pro-
tein kinase G (PKG), and dibutyryl cAMP (1 mM),
an activator of protein kinase A (PKA), did not in-
duce any observable morphological changes of
BPAEC even after 2 h (not shown; three experi-
ments). Also, we did not detect any change in the
shape of BPAEC after a 2 h treatment with the
Ca2þ ionophore, ionomycin (3 WM) (not shown;
three experiments), which could presumably activate
Ca2þ/calmodulin-dependent protein kinase(s).
We then tested whether colchicine (an inhibitor of
microtubule polymerization) and cytochalasin B (an
inhibitor of actin polymerization) could inhibit caly-
culin A e¡ects. As shown in Fig. 4, while 30 WM
colchicine did not a¡ect at all calyculin A-induced
shape changes, 30 WM cytochalasin B almost com-
pletely abolished such changes. This implicates that
calyculin A-induced morphological changes involved
actin rearrangement.
3.2. [Ca 2+]i homeostasis in calyculin A-treated
BPAEC
[Ca2þ]i elevation has been implicated in EC shape
changes [1^6]. Therefore, Ca2þ imaging experiments
were carried out to examine if there was any change
in [Ca2þ]i (indicated as fura-2 ratio (340/380), Fig. 5
right column) during the 2 h treatment of BPAEC
with calyculin A. Ca2þ imaging techniques enable
Fig. 5. Ca2þ imaging analysis of calyculin A-treated BPAEC. Fura-2-loaded BPAEC were treated with 100 nM calyculin A for vari-
ous times and [Ca2þ]i was measured. (Left and middle columns) Fluorescence at 340 nm and 380 nm excitation, respectively. (Right
column) 340/380 ratio is shown. Results shown are representative of at least four experiments.
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subcellular local changes of [Ca2þ]i to be observed,
as was obviously demonstrated in agonist-stimulated
calyculin-treated BPAEC (see Fig. 6 and description
below). No [Ca2þ]i elevation, gross or local, was ob-
served in the ¢rst few minutes after calyculin A ad-
dition (not shown), or throughout the 2 h calyculin
A treatment, within which time morphological
changes had been obvious (Fig. 5 right column).
Bleb formation and withdrawal, and cell rounding,
therefore, did not require [Ca2þ]i elevation. It should
be noted that the £uorescence at both 340 and 380
nm excitation wavelength increased with time (Fig. 5
left and middle columns). This was not unexpected as
the cells rounded up and increased in thickness,
hence emitting a stronger £uorescence.
As positive controls, we examined the Ca2þ signal-
ing of these cells in response to the purinergic recep-
tor agonist ATP (100 WM) [25] and the ryanodine
receptor-like Ca2þ channel agonist CEP (10 WM)
[21,26]. The rounded BPAEC (after around 1.5 h
calyculin A treatment) exhibited Ca2þ signals upon
ATP and CEP stimulation (Fig. 6), with each cell
responding to ATP and CEP with di¡erent speed
and magnitude of [Ca2þ]i elevation. Local (at cell
periphery) rise in [Ca2þ]i was readily detectable
when cells were stimulated with ATP.
3.3. Electrophysiological properties of calyculin
A-treated BPAEC
We next performed whole-cell patch clamp experi-
ments to investigate if there were any changes in the
electrophysiological properties of the calyculin A-
treated BPAEC. There were no signi¢cant changes
in the membrane potential of the calyculin-treated
blebby round cells (355V 5 mV) as compared to
control cells (345V 8 mV) (n=8^10). As the calycu-
lin A-treated cells exhibited bleb formation, change
in plasma membrane area was possible, which could
be estimated by measuring cell capacitance. How-
ever, the total surface area of plasma membrane of
control cells (11.6 V 0.6 pF) and calyculin A-treated
blebby round cells (11.3 V 0.3 pF) showed no signi¢-
cant di¡erence (n=8^10). Therefore, bleb formation
did not result from extra plasma membrane forma-
tion.
We were then interested in knowing whether the
rounded cells had ‘leaky’ or intact plasma mem-
brane. Even the late stage blebless round cells had
high input resistance (1.2V 0.1 G6) comparable to
that of the untreated cells (1.1 V 0.2 G6) (n=5^8),
suggesting integrity in their plasma membrane.
BPAEC, like other cultured EC types, exhibited
Fig. 6. Ca2þ signaling in calyculin A-treated BPAEC. ATP and CEP raised [Ca2þ]i (shown as ratio) in calyculin A-treated BPAEC.
(1) BPAEC were treated with 100 nM calyculin A for 1.5 h and became rounded. (2) Addition of 100 WM ATP for 1.5 min and (3,4)
decline of the Ca2þ signal 3 and 5.5 min later. (5,6) Addition of 10 WM CEP for 0.5 and 3 min. Results shown are representative of
three experiments.
BBAMCR 14839 3-5-02 Cyaan Magenta Geel Zwart
Y.M. Leung et al. / Biochimica et Biophysica Acta 1589 (2002) 93^103 99
strong inwardly rectifying Kþ (KIR) currents upon
hyperpolarizing voltage steps, with a reversal poten-
tial near 370 mV in physiological saline (Fig. 7)
[2,22]. BPAEC also exhibited small Ca2þ-dependent
outward Kþ currents upon depolarizing voltage steps
(Fig. 7) [23,27]. There were no signi¢cant qualitative
or quantitative changes in both KIR currents and
outward Kþ currents in the blebby round cells as
compared to the control cells (Fig. 7).
4. Discussion
Calyculin A, by inhibiting PP1 and 2A, indirectly
causes the enhancement of protein kinase activities
and consequently protein phosphorylation [8]. Caly-
culin A-induced shape changes in BPAEC are likely
to be mediated by protein phosphorylation: ¢rst, ca-
lyculin A is highly selective [7] and was shown here
to induce morphological changes at a low concentra-
tion (10 nM); second, such morphological changes
could be strongly inhibited by staurosporine, a pro-
tein kinase inhibitor. Since staurosporine is a non-
speci¢c protein kinase inhibitor, we attempted to
identify which particular protein kinase(s) was re-
sponsible for the calyculin A e¡ects. The participa-
tion of cAMP- and cGMP-dependent protein kinases
appeared unlikely because the calyculin e¡ects could
not be inhibited by H-8, a cyclic nucleotide-depen-
dent protein kinase inhibitor. This is consistent with
the ¢nding that dibutyryl cAMP and 8-Br-cGMP
could not mimic calyculin A. GF-109203 X, a spe-
ci¢c inhibitor of PKC, showed no inhibitory e¡ect at
all on the formation of the early-stage blebby round
cells. In accord with this result, PMA also failed to
mimic calyculin A. These data suggest that PKC ac-
tivity was not essential for the initiation of morpho-
logical changes. Participation of tyrosine kinases is
also unlikely, as genistein (30 WM), a speci¢c tyrosine
kinase inhibitor, did not interfere with the calyculin
A e¡ects (not shown).
Although [Ca2þ]i elevation has been well known to
trigger contraction of many EC types [1^6], it did not
seem to trigger contraction of rat pulmonary micro-
vascular EC (while in the same work it caused con-
traction of rat pulmonary artery EC) [14], suggesting
the presence of a [Ca2þ]i-independent shape change
mechanism in certain EC types. We showed here that
ionomycin did not cause morphological changes in
BPAEC. Consistently, using the Ca2þ imaging tech-
nique, we found that calyculin A-induced shape
changes were not associated with any local or global
changes in [Ca2þ]i, providing direct evidence of a
[Ca2þ]i-independent shape change mechanism in
EC. Therefore, such shape change mechanism pre-
Fig. 7. Kþ currents in untreated and calyculin A-treated
BPAEC. Holding potential was 370 mV and voltage steps (20
mV increments) were delivered from 3160 to +40 mV. (A) Cur-
rents in a DMSO-treated control cell (20 min^1 h). (B) Cur-
rents in a calyculin A (100 nM)-treated cell (20 min^1 h). (C)
I^V plots of results from A and B. a, control; b, calyculin A.
In C, steady-state currents (at 230 ms) are normalized by cell
membrane capacitance to yield current densities (pA/pF). Re-
sults are meanVS.E.M. of 8^10 cells.
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sumably did not involve Ca2þ/calmodulin-dependent
protein kinases.
Taken together, the data suggest that the calyculin
A-induced shape changes were unrelated to [Ca2þ]i
elevation, and mediated in part by some staurospo-
rine-sensitive protein kinases other than PKA, PKG,
PKC and Ca2þ/calmodulin-dependent protein ki-
nases. The participation by atypical PKC (e.g.
PKCj), however, may be possible, since this PKC
isoform is Ca2þ-independent and not activated by
PMA [28]. Nevertheless, the fact that GF-109203
X, a potent inhibitor of all known PKC isoforms
[29], did not show any inhibition may argue against
this proposal.
OA (a PP1 and 2A inhibitor structurally unrelated
to calyculin A) was ine¡ective in causing any mor-
phological change in BPAEC. Calyculin A and OA
have di¡erent potencies in inhibiting protein phos-
phatases: calyculin A inhibits PP1 and PP2A with
similar potency (IC50 values of 2 and 1 nM, respec-
tively) [7] while OA is considerably less potent in
inhibiting PP1 (IC50 values from 60 to 500 nM)
than PP2A (IC50 value of 1 nM) [7,30]. Inhibition
of PP1 therefore may be more important than inhi-
bition of PP2A in mediating calyculin A-induced
morphological changes. Interestingly, PP1 catalytic
subunit N has been shown to interact directly with
actin^myosin complex in BPAEC [31]. On the other
hand, we cannot rule out the possibility that the
calyculin A-induced shape changes may involve
some mechanisms independent from PP1 and PP2A
inhibition. In bovine pulmonary microvascular EC,
PP2B appears to regulate thrombin-induced cell
shape changes [32].
Much milder changes (i.e. cells slightly contract
but still retain the cobblestone morphology) have
been reported in agonist- and PMA-treated EC, in-
cluding BPAEC [33^35]. MLC phosphorylation and
the subsequent actin^myosin interaction have been
implicated in these shape changes. However, Diwan
et al. [13] provided strong evidence that the small
contraction of rat pulmonary microvascular EC in-
duced by calyculin A was independent of MLC ki-
nase activity. Calyculin A (10^100 nM)-induced dras-
tic shape changes in our case were also not inhibited
by ML-7 (10 WM) (not shown), further suggesting the
presence of an EC shape change mechanism indepen-
dent from MLC kinase activity. We proceeded to
show that calyculin A e¡ects could be abolished by
cytochalasin B, suggesting that actin polymerization
primarily accounted for the shape changes. It is note-
worthy that calyculin A (10 nM) has previously been
shown to cause only very mild contraction in
BPAEC (also CCL-209 from ATCC) [12]. The cause
of this discrepancy is unknown, but could be di¡er-
ences in cell culture medium and its supplements,
which might somehow a¡ect cell properties.
Cells undergoing apoptosis form surface mem-
brane blebs (called apoptotic bodies), which eventu-
ally pinch o¡ from the cell [36,37]. The blebs formed
in the calyculin A-treated BPAEC, by contrast,
slowly withdrew into the cell as cell rounding became
more prominent. Hence, these blebs are unlikely to
be apoptotic bodies. Rounding is a phenomenon
sometimes associated with cell necrosis. However,
the calyculin A-treated rounded BPAEC had the fol-
lowing properties which are not expected of necrotic
membranes [36,37]: (A) the ability to exclude trypan
blue, (B) high input resistance similar to that of the
control cells, (C) negative values of membrane po-
tential comparable to those of the untreated cells,
(D) Kþ currents similar to those of control cells,
and (E) [Ca2þ]i similar to that of the control cells.
A and B are indicative of a structurally intact plasma
membrane, while C^E further suggest that the plas-
ma membrane was able to maintain appropriate
ionic £uxes (Naþ, Kþ and Ca2þ) and was hence func-
tionally intact.
The vascular EC layer provides a barrier to the
exchanges between blood and tissues. During in£am-
mation, EC respond by contracting to form small
inter-EC gaps, and thereby enhancing vascular per-
meability [1^6]. It is generally believed that in£am-
matory agents (e.g. thrombin and histamine) cause
EC contraction by (1) raising [Ca2þ]i, which in turn
causes MLC phosphorylation and actin^myosin in-
teraction, and/or (2) activating PKC, which subse-
quently leads to loosening of cell^cell and cell^matrix
contact ([1^6,38] ; see [34] for such a mechanism in
BPAEC). Calyculin A-induced cell shape changes in
our case could be driven by some unknown kinases
and actin polymerization, and did not require [Ca2þ]i
elevation. It therefore represents an additional mech-
anism of EC shape changes. Although these shape
changes may appear to be too drastic to be within
the realm of pathophysiological signi¢cance (in£am-
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mation), they do reveal how normal EC morphology
may be maintained. In untreated resting EC, the ac-
tivities of these unknown kinases could lead to cell
retraction and rounding, but are o¡set by the con-
tinuous activities of calyculin A-sensitive protein
phosphatases. Why BPAEC exhibit such a rapid dy-
namic equilibrium is uncertain. It is possible that
these kinases are constitutively maintaining cellular
convexity, a proposal in agreement with the fact that
staurosporine alone caused BPAEC to £atten (our
unpublished observation). Meanwhile, it is also ex-
pected that lower concentrations of calyculin A
would promote milder shape changes. In line with
this, there was evidence that thrombin could inhibit
calyculin A-sensitive protein phosphatases in human
umbilical vein EC [39]. To what extent the [Ca2þ]i-
independent mechanism, as described in this report,
contributes to the thrombin-induced EC shape
changes, awaits further studies.
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